mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

NCT03196986 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

517

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: mil60
DRUG: Bevacizumab

Sponsor

Beijing Mabworks Biotech Co., Ltd.

Collaborators

[object Object]